Literature DB >> 16607571

Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling.

Wayne C Guida1, Andrew D Hamilton, Justin W Crotty, Saïd M Sebti.   

Abstract

Using MacroModel, peptide, peptidomimetic and non-peptidomimetic inhibitors of the zinc metalloenzyme, farnesyltransferase (FTase), were docked into the enzyme binding site. Inhibitor flexibility, farnesyl pyrophosphate substrate flexibility, and partial protein flexibility were taken into account in these docking studies. In addition to CVFM and CVIM, as well as our own inhibitors FTI-276 and FTI-2148, we have docked other farnesyltransferase inhibitors (FTIs) including Zarnestra, which presently is in advanced clinical trials. The AMBER* force field was employed, augmented with parameters that were derived for zinc. A single binding site model that was derived from the crystal structure of CVFM complexed with farnesyltransferase and farnesylpyrophosphate was used for these studies. The docking results using the lowest energy structure from the simulation, or one of the lowest energy structures, were generally in excellent agreement with the X-ray structures. One of the most important findings of this study is that numerous alternative conformations for the methionine side chain can be accommodated by the enzyme suggesting that the methionine pocket can tolerate groups larger than methionine at the C-terminus of the tetrapeptide and suggesting alternative locations for the placement of side chains that may improve potency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607571     DOI: 10.1007/s10822-005-9030-2

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  15 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.

Authors:  S Jane deSolms; Terrence M Ciccarone; Suzanne C MacTough; Anthony W Shaw; Carolyn A Buser; Michelle Ellis-Hutchings; Christine Fernandes; Kelly A Hamilton; Hans E Huber; Nancy E Kohl; Robert B Lobell; Ronald G Robinson; Nancy N Tsou; Eileen S Walsh; Samuel L Graham; Lorena S Beese; Jeffrey S Taylor
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

3.  Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Authors:  R B Lobell; C A Omer; M T Abrams; H G Bhimnathwala; M J Brucker; C A Buser; J P Davide; S J deSolms; C J Dinsmore; M S Ellis-Hutchings; A M Kral; D Liu; W C Lumma; S V Machotka; E Rands; T M Williams; S L Graham; G D Hartman; A I Oliff; D C Heimbrook; N E Kohl
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

4.  Protein farnesyltransferase: structure and implications for substrate binding.

Authors:  P Dunten; U Kammlott; R Crowther; D Weber; R Palermo; J Birktoft
Journal:  Biochemistry       Date:  1998-06-02       Impact factor: 3.162

5.  Crystal structure of protein farnesyltransferase at 2.25 angstrom resolution.

Authors:  H W Park; S R Boduluri; J F Moomaw; P J Casey; L S Beese
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

Review 6.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

Authors:  J B Gibbs; A Oliff; N E Kohl
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

7.  The basis for K-Ras4B binding specificity to protein farnesyltransferase revealed by 2 A resolution ternary complex structures.

Authors:  S B Long; P J Casey; L S Beese
Journal:  Structure       Date:  2000-02-15       Impact factor: 5.006

8.  Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue.

Authors:  C L Strickland; W T Windsor; R Syto; L Wang; R Bond; Z Wu; J Schwartz; H V Le; L S Beese; P C Weber
Journal:  Biochemistry       Date:  1998-11-24       Impact factor: 3.162

Review 9.  Farnesyltransferase inhibitors as anticancer agents: current status.

Authors:  Kuichun Zhu; Andrew D Hamilton; Saïd M Sebti
Journal:  Curr Opin Investig Drugs       Date:  2003-12

10.  Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.

Authors:  S B Long; P J Casey; L S Beese
Journal:  Biochemistry       Date:  1998-07-07       Impact factor: 3.162

View more
  3 in total

Review 1.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Imidazole-containing farnesyltransferase inhibitors: 3D quantitative structure-activity relationships and molecular docking.

Authors:  Aihua Xie; Srinivas Odde; Sivaprakasam Prasanna; Robert J Doerksen
Journal:  J Comput Aided Mol Des       Date:  2009-05-29       Impact factor: 3.686

3.  Matrix metalloproteinase-1 contribution to sarcoma cell invasion.

Authors:  Nandor Garamszegi; Susanna P Garamszegi; Sean P Scully
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.